People: ArQule Inc (ARQL.W)
ARQL.W on CBOE When Trading NASDAQ Global Select Market
2.76USD
23 May 2013
2.76USD
23 May 2013
Price Change (% chg)
$0.02 (+0.73%)
$0.02 (+0.73%)
Prev Close
$2.74
$2.74
Open
$2.76
$2.76
Day's High
$2.76
$2.76
Day's Low
$2.76
$2.76
Volume
100
100
Avg. Vol
1,082
1,082
52-wk High
$6.90
$6.90
52-wk Low
$1.99
$1.99
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Patrick Zenner |
65 | 2004 | Independent Chairman of the Board |
Peter Lawrence |
49 | 2008 | President, Chief Operating Officer |
Paolo Pucci |
52 | 2008 | Chief Executive Officer, Director |
Brian Schwartz |
51 | 2008 | Chief Medical Officer |
Timothy Barabe |
59 | 2001 | Independent Director |
Susan Kelley |
58 | 2011 | Independent Director |
Ronald Lindsay |
65 | 2005 | Independent Director |
Michael Loberg |
64 | 2007 | Independent Director |
William Messenger |
51 | 2005 | Independent Director |
Biographies
| Name | Description |
|---|---|
Patrick Zenner |
Mr. Patrick J. Zenner is an Independent Chairman of the Board of ArQule, Inc. Mr. Zenner was named Chairman of the Board in May 2004 and has been a director since 2002. Mr. Zenner retired in 2001 from the position of President and Chief Executive Officer of Hoffmann-La Roche Inc., North America. Hoffmann-La Roche Inc., based in Nutley, N.J., is the prescription drug unit of the Roche Group. Mr. Zenner held various executive positions during his 32-year career with the company. Mr. Zenner is currently on the Board of Trustees of Creighton University and is Chairman of the Board of Trustees of Fairleigh Dickinson University. In addition, Mr. Zenner is a member of the Boards of Directors of West Pharmaceutical Services, Inc., and Par Pharmaceuticals, Inc. In 2010, he resigned from the boards of Geron Corporation, Xoma Ltd. and Exact Sciences, Inc. Until its sale in September 2009, Mr. Zenner was a director of CuraGen Corporation. He has a B.S./B.A. from Creighton University and an M.B.A. from Fairleigh Dickinson University. |
Peter Lawrence |
Mr. Peter S. Lawrence is President, Chief Operating Officer of ArQule, Inc. Mr. Lawrence joined ArQule as Executive Vice President and Chief Business Officer in April 2006. He was named Chief Operating Officer in October 2007 and President in April 2008. Previously he was at Pod Venture Partners, an international venture capital firm which he co-founded in 2001 and where he most recently served as general partner. He helped drive the strategic growth of that firm, including deal sourcing and structuring, syndication and business expansion activities. Previously, Mr. Lawrence was an attorney and partner at Mintz, Levin, Cohn, Ferris Glovsky and Popeo, P.C., from 1991 to 2001. At Mintz Levin, he served as external corporate counsel to public and private companies, managed a transactional legal practice and provided strategic guidance to clients through periods of rapid growth and transformative corporate events. His public financing experiences include the initial public offering and numerous financings for America Online Inc. (AOL), as well as public financings for Biogen, Human Genome Sciences, Hybridon and many other companies. He worked on numerous mergers and acquisitions, including Roche/Compuchem, AOL/Time Warner, Steinway Piano, DEC/Intel, and Mitotix/GPC Biotech. Mr. Lawrence worked at Gaston & Snow from 1989 to 1991 in the firm’s Corporate Law Department. He holds a Bachelor’s degree from Amherst College and a J.D. from Boston University School of Law. |
Paolo Pucci |
Mr. Paolo Pucci is Chief Executive Officer, Director of ArQule Inc. Previously Mr. Pucci was senior vice president of Bayer Pharmaceuticals Global Specialty Business Unit, president of U.S. Pharmaceutical Operations and a member of the Bayer Pharmaceuticals Global Management Committee. At Bayer, Mr. Pucci was involved in a broad range of activities related to Nexavar ® (sorafenib), an oral multiple kinase inhibitor to treat liver and kidney cancers. These activities included clinical development, regulatory review, corporate alliance management, product launch and marketing. Mr. Pucci joined Bayer as head of its Italian Pharmaceutical operations in 2001. Prior to Bayer, Mr. Pucci held positions of increasing responsibility with Eli Lilly, culminating with his appointment as managing director, Eli Lilly Sweden AB. At Lilly, his responsibilities included operations, sales, marketing and strategic planning. On November 1, 2011, Mr. Pucci was appointed to the Board of Directors of Dyax Corporation. Mr. Pucci holds an MBA from the University of Chicago and is a graduate of the Universita’ Degli Studi Di Napoli in Naples, Italy. |
Brian Schwartz |
Dr. Brian Schwartz, M.D., is Chief Medical Officer of ArQule Inc. Prior to Ziopharm, Dr. Schwartz held a number of positions at Bayer Healthcare. His experience in oncology has encompassed the clinical development of novel cytostatic, cytotoxic and immunological agents. At Bayer, Dr. Schwartz was a key physician responsible for the global clinical development of Nexavar® (sorafenib). He has regulatory experience working with the FDA’s Oncology Division, the European Medicines Agency (EMA), and numerous other health authorities. Dr. Schwartz has also been responsible for U.S. clinical and regulatory activities, including Phase 4 studies and interactions with the National Cancer Institute and other oncology cooperative groups. Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, practiced medicine, and worked at the University of Toronto prior to his career in industry. |
Timothy Barabe |
Mr. Timothy C. Barabe is an Independent Director of ArQule, Inc since November 2001. Mr. Barabe is currently Executive Vice President and Chief Financial Officer of Affymetrix, Inc. Previously, from July 2006 until March 2010, he was Senior Vice President and Chief Financial Officer of Human Genome Sciences, Inc. He was with Regent Medical Limited, a U.K.-based, privately owned, surgical supply company, where he was Chief Financial Officer, from 2004-2006. Mr. Barabe served with Novartis AG from 1982 through August 2004 in a succession of senior executive positions in finance and general management, most recently as the Chief Financial Officer of Sandoz GmbH, the generic pharmaceutical subsidiary of Novartis. Mr. Barabe received his B.B.A. degree from the University of Massachusetts (Amherst) and his M.B.A. degree from the University of Chicago. |
Susan Kelley |
Dr. Susan L. Kelley, M.D., is an Independent Director of ArQule, Inc since April 27, 2011. From 2001 to 2008, Dr. Kelley was employed by Bayer Healthcare Pharmaceuticals and Bayer-Schering Pharma in Germany and the United States serving as Vice President, Global Strategic Drug Development, Cancer and Metabolics from April 2001 to May 2002 and from May 2002 until June 2008 as Vice President, Global Clinical Development and Therapeutic Area Head-Oncology. From July 2008 to March 2011, she was Chief Medical Officer of The Multiple Myeloma Research Foundation/Consortium. Most recently, she has been an independent consultant to the pharmaceutical and biotechnology industries in the field of oncology drug development and strategy. Dr. Kelley has an A.B. Biology, magna cum laude from Colgate University and an M.D. from Duke University School of Medicine. She was a Fellow in Medical Oncology and Clinical Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School and a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine where she also served as a Clinical Assistant Professor of Medicine. |
Ronald Lindsay |
Dr. Ronald M. Lindsay, Ph.D., is an Independent Director of ArQule, Inc since June 2005. He currently operates Milestone Consulting, a biopharmaceutical consulting enterprise. He is a director and since October, 2009, has served as Executive Vice President of Research and Development of Sequenom Inc. Dr. Lindsay is also a director of HistoRx Inc., and Executive Chairman of NeuroCentRx Pharmaceuticals Ltd., Edinburgh, Scotland, which he co-founded in 2008. Dr. Lindsay was previously Chief Scientific Officer and Vice President, Research and Development, at diaDexus Inc. from 2000 to 2004, and held a number of positions at Millennium Pharmaceuticals, Inc., including Senior Vice President, Biotherapeutics, from 1997 to 2000. At Regeneron Pharmaceuticals, where he worked from 1989 to 1997, he was a founding scientist and Vice President, Neurobiology. Dr. Lindsay also worked at the Sandoz Institute for Medical Research, London from 1984 to 1989, where he was Head of Cell Biology. Dr. Lindsay completed post-doctoral work at the Friedrich Miescher Institute, and he holds a B.Sc. (Hons) in chemistry from the University of Glasgow and a Ph.D. in biochemistry from the University of Calgary. |
Michael Loberg |
Dr. Michael D. Loberg, Ph.D., is an Independent Director of ArQule, Inc since January 2007. Dr. Loberg is a member of the Board of Directors of Inotek Pharmaceuticals Corporation, a developer of ophthalmic medicines, and recently served as its Interim Chief Executive Officer. Previously, he served as Chief Executive Officer and a member of the Board of Directors of NitroMed, Inc., a pharmaceutical company, from September 1997 to March 2006 and as its President from September 2003 to March 2006. From 1979 to 1997, Dr. Loberg held a number of senior management positions at Bristol-Myers Squibb, including President of Bristol-Myers Squibb’s Oncology and Immunology, U.S. Primary Care, Northern Europe, Specialty Pharmaceuticals and Squibb Diagnostics divisions, as well as director and Vice President, E.R. Squibb & Sons Research and Development. Prior to his employment with Bristol-Myers Squibb, Dr. Loberg was an associate professor of medicine and pharmacy from 1976 to 1979 and an assistant professor from 1973 to 1976 at the University of Maryland. Since 2004, Dr. Loberg has been a director of Kereos, Inc., a developer of targeted molecular imaging agents and therapeutics. Until May 2009 when he did not stand for reelection, he was a director of AMAG, a biotechnology company focused in renal disease. He holds a B.S. in Chemistry from Trinity College and a Ph.D. in Chemistry from Washington University. |
William Messenger |
Dr. William G. Messenger, D. Min., is an Independent Director of ArQule, Inc since January 2005. He chairs the Company's Compensation, Nominating and Governance Committee and is a member of its Audit Committee. He has been the owner and managing director of the Lexington Sycamore Group, consultants in the fields of business strategy, organization and leadership, since 1994. Dr. Messenger also serves as the Executive Editor of the Theology of Work Project, a small international organization conducting research and publication in the field of business ethics. He currently serves as adjunct professor of business ethics at Rensselaer Polytechnic Institute and a lecturer in business ethics at Holy Cross College. From 1999 to 2008, Dr. Messenger served as Director of the Mockler Center for Faith and Ethics in the Workplace at Gordon-Cornwell Theological Seminary. Dr. Messenger received a B.S. in Physics with highest honors from Case Western Reserve University, an M.B.A. with high distinction from Harvard Business School, a Master of Divinity degree, summa cum laude, from Boston University School of Theology, and a Doctor of Ministry from Gordon-Conwell Theological Seminary. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Patrick Zenner |
-- |
Peter Lawrence |
1,181,000 |
Paolo Pucci |
1,967,420 |
Brian Schwartz |
1,031,900 |
Timothy Barabe |
-- |
Susan Kelley |
-- |
Ronald Lindsay |
-- |
Michael Loberg |
-- |
William Messenger |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Patrick Zenner |
0 | 0 |
Peter Lawrence |
0 | 0 |
Paolo Pucci |
0 | 0 |
Brian Schwartz |
0 | 0 |
Timothy Barabe |
0 | 0 |
Susan Kelley |
0 | 0 |
Ronald Lindsay |
0 | 0 |
Michael Loberg |
0 | 0 |
William Messenger |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
LOBERG MICHAEL D |
431 | $2.90 |
BARABE TIMOTHY C |
250 | $3.00 |
LOBERG MICHAEL D |
387 | $2.58 |
BARABE TIMOTHY C |
465 | $2.58 |
LOBERG MICHAEL D |
254 | $2.46 |
BARABE TIMOTHY C |
304 | $2.46 |
LOBERG MICHAEL D |
1,260 | $2.48 |
BARABE TIMOTHY C |
2,419 | $2.48 |
LOBERG MICHAEL D |
488 | $2.56 |
LAWRENCE PETER S |
8,616 | $2.54 |
WEISKOPF ROBERT J |
1,139 | $2.54 |
SCHWARTZ BRIAN |
1,111 | $2.54 |
WEISKOPF ROBERT J |
12,799 | $0.00 |
LAWRENCE PETER S |
25,000 | $0.00 |
SCHWARTZ BRIAN |
30,000 | $0.00 |
BARABE TIMOTHY C |
478 | $2.51 |
LOBERG MICHAEL D |
398 | $2.51 |
LOBERG MICHAEL D |
214 | $2.92 |
LOBERG MICHAEL D |
437 | $2.86 |
LOBERG MICHAEL D |
222 | $2.81 |
LOBERG MICHAEL D |
1,747 | $2.36 |
BARABE TIMOTHY C |
3,367 | $2.36 |
LOBERG MICHAEL D |
510 | $2.45 |
LOBERG MICHAEL D |
249 | $2.51 |
BARABE TIMOTHY C |
298 | $2.51 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
